This means it works like a natural hormone in the body called glucagon-like peptide-1 (GLP-1)
FDA is working with its state regulatory partners and will continue to communicate with compounders regarding these concerns
New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al
Food and Drug Administration (FDA) officially approved the GLP-1 medication Ozempic to help reduce the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease
Frequently asked questions How should PT-141 10mg be reconstituted
Fournier JP, Azoulay L, Yin H, et al